CORRECTION Open Access



Correction to: Prognostic nomogram for overall survival in upper urinary tract urothelial carcinoma (UTUC) patients treated with chemotherapy: a SEER-based retrospective cohort study

Cong Tian^{1,2†}, Jun Liu^{1,2†}, Lizhe An^{1,2}, Yang Hong^{1,2} and Qingquan Xu^{1,2*}

Correction to: BMC Urology (2023) 23:1 https://doi.org/10.1186/s12894-022-01172-8

Following publication of the original article [1], In table 1, First line, second column, "Received chemotherapy" were supposed to be "Unreceived chemotherapy". First line, third column, "Unreceived chemotherapy" were supposed to be "Received chemotherapy".

The original article has been corrected.

Table 1 Demographics, clinicopathologic characteristics, and therapeutic information of the enrolled UTUC patients.

Characteristics	Unreceived chemotherapy	Received chemotherapy	Total	P value
Number of patients (%) Age (years)	4441 (77.9%)	1257 (22.1%)	5698 (100%)	< 0.001*
Mean (SD)	72.1 (11.0)	67.2 (10.4)	71.1 (11.1)	

The online version of the original article can be found at https://doi.org/10.1186/s12894-022-01172-8.

Qingquan Xu

xuqingquan@bjmu.edu.cn

¹Department of Urology, Peking University People's Hospital, Beijing 100034, China

²Peking University Applied Lithotripsy Institute, Peking University, 133# Fuchengmen Neidajie Street, XiCheng District, Beijing 100034, China

Table 1 Demographics, clinicopathologic characteristics, and therapeutic information of the enrolled UTUC patients.

Characteristics	Unreceived chemotherapy	Received chemotherapy	Total	P value
Sex				0.076
Female	1943 (43.8%)	514 (40.9%)	2457 (43.1%)	
Male	2498 (56.2%)	743 (59.1%)	3241 (56.9%)	
Race				< 0.001*
White	3887 (87.5%)	1051 (83.6%)	4938 (86.7%)	
Black	185 (4.2%)	53 (4.2%)	238 (4.2%)	
Other	369 (8.3%)	153 (12.2%)	522 (9.2%)	
Marital status				< 0.001*
Married	2658 (59.9%)	890 (70.8%)	3548 (62.3%)	
Divorced/ widowed/ Separated	1363 (30.7%)	248 (19.7%)	1611 (28.3%)	
Unmarried/ Single	420 (9.5%)	119 (9.5%)	539 (9.5%)	
Primary Site				0.358
Renal Pelvis	2933 (66.0%)	812 (64.6%)	3745 (65.7%)	
Ureter	1508 (34.0%)	445 (35.4%)	1953 (34.3%)	
Grade				< 0.001*



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*}Correspondence:

Tian et al. BMC Urology (2023) 23:110 Page 2 of 2

Table 1 Demographics, clinicopathologic characteristics, and therapeutic information of the enrolled UTUC patients.

Characteristics	Unreceived	Received	Total	P value
	chemotherapy			
Grade I	246 (5.5%)	21 (1.7%)	267	
Consider II	001 (10 00/)	77 (6 10/)	(4.7%)	
Grade II	801 (18.0%)	77 (6.1%)	878 (15.4%)	
Crada III	1252 (20 20/)	404 (22 10/)		
Grade III	1253 (28.2%)	404 (32.1%)	1657 (29.1%)	
Grade IV	2141 (40 20/)	755 (60 10/)		
Grade IV	2141 (48.2%)	755 (60.1%)	2896 (50.8%)	
T C** **			(30.6%)	4 O OO1:
T Stage	1642 (27.00)	177 (1 4 10/)	1010	< 0.0013
T1	1642 (37.0%)	177 (14.1%)	1819	
T2	001 (10 00/)	122 (10 50()	(31.9%)	
T2	881 (19.8%)	132 (10.5%)	1013	
T2	1500 (26 00/)	604 (55 20/)	(17.8%)	
T3	1598 (36.0%)	694 (55.2%)	2292	
Τ4	220 /7 20/\	254 (20.20)	(40.2%)	
T4	320 (7.2%)	254 (20.2%)	574 (10.1%)	
VI Ctago			(10.170)	Z 0 001÷
N Stage	4122 (02.00()	770 (62 004)	4003	< 0.0013
N0	4123 (92.8%)	779 (62.0%)	4902	
N11	106 (4 20/)	262 (20.00/)	(86.0%)	
N1	186 (4.2%)	262 (20.8%)	448 (7.00%)	
NO	122 (2.00()	216 (17 20()	(7.9%)	
N2	132 (3.0%)	216 (17.2%)	348	
M Charac			(6.1%)	.0.0013
M Stage	1206 (06 50/)	1024 (01 50/)	5210	< 0.001
MO	4286 (96.5%)	1024 (81.5%)	5310	
	4.5.5 (0.50()	000 (4.0 50()	(93.2%)	
M1	155 (3.5%)	233 (18.5%)	388	
D 1: .:			(6.8%)	1 000
Radiation				1.000
No/Unknown	19 (0.4%)	6 (0.5%)	25	
			(0.4%)	
Yes	4422 (99.6%)	1251 (99.5%)	5673	
			(99.6%)	0.001
Surgical methods				< 0.001*
of the primary site				
No	26 (0.6%)	124 (0.0%)	150	
NU	26 (0.6%)	124 (9.9%)	150 (2.6%)	
Local Mass	163 (3.7%)	49 (3.9%)	212	
resection/	(3./70)	コ ラ (コ.ガ70)	(3.7%)	
destruction			(3.7 70)	
Partial	472 (10.6%)	114 (9.1%)	586	
nephrectomy/	2 (. 0.070)	(2 /0)	(10.3%)	
ureterectomy				
Radical	2600 (58.5%)	586 (46.6%)	3186	
nephroureterec-	(/-/		(55.9%)	
tomy				
Radical	1014 (22.8%)	324 (25.8%)	1338	
nephrectomy			(23.5%)	
Multivisceral	166 (3.7%)	60 (4.8%)	226	
resection			(4.0%)	
Surgery of				< 0.001*
Lymph nodes				
(LNs)				

Table 1 Demographics, clinicopathologic characteristics, and therapeutic information of the enrolled UTUC patients.

Characteristics	Unreceived chemotherapy	Received chemotherapy	Total	P value
No	3413 (76.9%)	716 (57.0%)	4129 (72.5%)	
1 to 3 regional LNs removed	610 (13.7%)	268 (21.3%)	878 (15.4%)	
4 or more regional LNs removed	418 (9.4%)	273 (21.7%)	691 (12.1%)	

^{*}P<0.05 indicating statistical significance.

Accepted: 30 March 2023 Published online: 24 June 2023

References

 Tian C, Liu J, An L, Hong Y, Xu Q. Prognostic nomogram for overall survival in upper urinary tract urothelial carcinoma (UTUC) patients treated with chemotherapy: a SEER-based retrospective cohort study. BMC urology. 2023 Dec; 33(1):1-2.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.